Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors (Q44188982)

30 November 2017

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors (English)

1 reference

30 November 2017

0 references

1 reference

6

Jay N Cohn

1 reference

30 November 2017

Aldo P Maggioni

1

1 reference

30 November 2017

Inder Anand

2

1 reference

30 November 2017

Sidney O Gottlieb

3

1 reference

30 November 2017

Roberto Latini

4

1 reference

30 November 2017

Gianni Tognoni

5

1 reference

30 November 2017

Val-HeFT Investigators (Valsartan Heart Failure Trial)

7

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

Journal of the American College of Cardiology

30 November 2017

1 reference

30 November 2017

40

1 reference

30 November 2017

8

1 reference

30 November 2017

1414-1421

1 reference

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902304-5

7 January 2021

Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902304-5

7 January 2021

Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902304-5

7 January 2021

Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902304-5

7 January 2021

Proposed update of angiotensin receptor nomenclature.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902304-5

7 January 2021

Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902304-5

7 January 2021

Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902304-5

7 January 2021

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902304-5

7 January 2021

Evidence of inadequate investigation and treatment of patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902304-5

7 January 2021

Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902304-5

7 January 2021

Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902304-5

7 January 2021

Survey on heart failure in Italian hospital cardiology units. Results of the SEOSI study. SEOSI Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902304-5

7 January 2021

Comparison of one-year outcome in women versus men with chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902304-5

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902304-5

7 January 2021

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902304-5

7 January 2021

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902304-5

7 January 2021

Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902304-5

7 January 2021

10.1016/S0735-1097(02)02304-5

Identifiers

DOI

1 reference

release_htdefeliwvg5vpr4pzc6zjkyq4

30 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/htdefeliwvg5vpr4pzc6zjkyq4

24 November 2022

mapped directly with Wikidata item

1 reference